Randomized Study of Triple Therapy vs Sildenafil Dose Optimization in Pulmonary Arterial Hypertension

NCT07713914 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

DRUG: Prostacyclin Pathway Agent
DRUG: Sildenafil Dose Optimization

Sponsor

University of Sao Paulo General Hospital